Primary osteogenic sarcoma: eight-year experience with adjuvant chemotherapy.

Area of Science:

• Oncology
• Pediatric Oncology
• Surgical Oncology

Background:

• Osteogenic sarcoma (bone cancer) is a significant challenge in pediatric and young adult oncology.
• Adjuvant chemotherapy has been explored to improve survival rates for extremity osteosarcoma.
• Optimizing chemotherapy regimens and patient selection is crucial for enhancing treatment efficacy.

Purpose of the Study:

• To evaluate the impact of evolving adjuvant chemotherapy strategies on cure rates in patients with primary osteogenic sarcoma of the extremity.
• To assess the effectiveness of using preoperative chemotherapy response to guide postoperative treatment selection.
• To determine if a tailored approach can further improve disease-free survival in osteosarcoma patients.

Main Methods:

• Retrospective analysis of 185 patients (≤21 years) with extremity osteogenic sarcoma treated with adjuvant chemotherapy since 1973.
• Comparison of outcomes across three distinct chemotherapy protocols with increasing treatment intensity and selection criteria.
• Evaluation of disease-free survival rates based on chemotherapy regimens, including high-dose methotrexate and response-guided postoperative therapy.

Main Results:

• Initial adjuvant chemotherapy yielded a 48% disease-free rate (median 7 years) in 52 patients.
• Escalated high-dose methotrexate pre-amputation/resection improved the disease-free rate to 80% (median 4 years) in 54 patients.
• Response-guided postoperative chemotherapy achieved a 92% disease-free rate (median 2 years) in 79 patients.

Conclusions:

• Adjuvant chemotherapy plays a vital role in increasing cure rates for osteogenic sarcoma.
• Preoperative chemotherapy response is a valuable indicator for selecting effective postoperative adjuvant chemotherapy.
• A tailored, response-guided approach to chemotherapy offers the highest potential for improving cure rates in osteogenic sarcoma.